Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare, genetic intellectual disability syndrome characterized by macrocephaly, hypotonia, dysmorphic facial features (wide forehead, ptosis, downslanting palpebral fissures, enlarged and calcified external ears, large jaw), sparse body hair, tall stature, and intellectual disability. Hearing loss, insulin-resistant diabetes, and progressive distal muscle wasting (leading to joint contractures) have also been reported in adulthood. Rare manifestations include behavioral abnormalities (aggression and restlessness), hypothyroidism, cerebral calcification, ataxia, and peripheral neuropathy.
Features include always present findings: Global developmental delay, Elevated circulating alpha-fetoprotein concentration, and Delayed speech and language development; and very common findings: Epicanthus, Hearing loss (hearing impairment), Deeply set eye, and Sparse body hair and others. 86 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Brain and nerves | 11 | Seizure, Ataxia, Aggressive behavior |
ZBTB20 function has not been fully characterized.
Primrose syndrome is caused by mutations in the ZBTB20 gene on chromosome 3.
No genotype-phenotype correlations have been identified.
No consensus clinical diagnostic criteria for Primrose syndrome have been published.
Primrose syndrome should be suspected in individuals with the following clinical, laboratory, and imaging findings.
Clinical findings
Source: GeneReviews — "Primrose Syndrome"
No approved treatments are currently available for Primrose syndrome. The disease remains an area of unmet medical need.
No clinical practice guidelines for Primrose syndrome have been published. Evaluations Following Initial Diagnosis To establish the extent of disease and needs in an individual diagnosed with Primrose syndrome, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended. Table 4. Recommended Evaluations Following Initial Diagnosis in Individuals with Primrose Syndrome
Table 6. Recommended Surveillance for Individuals with Primrose Syndrome
System/Concern |
|---|
No clinical trials have been registered for Primrose syndrome.
146 publications have been identified in PubMed for Primrose syndrome. Research spans Review / Meta-Analysis (32%), Basic Science / Preclinical (32%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 47 | 32% |
Data assembled from 8 of 12 sources · Last updated Sep 18, 2026, 6:42 PM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Primrose syndrome
Bones and joints | 8 | Skeletal muscle atrophy, Joint hypermobility, Generalized osteoporosis |
Head and neck | 6 | Absent facial hair, Hypoplasia of the maxilla, Increased size of the mandible |
Muscles | 5 | Flexion contracture, Hip contracture, Low muscle tone (hypotonia) |
Hormones | 4 | Diabetes mellitus, Hypergonadotropic hypogonadism, Hypothyroidism |
Eyes | 3 | Strabismus, Ptosis, Posterior polar cataract |
Arms and legs | 2 | Dystrophic fingernails, Short distal phalanx of finger |
Ears | 1 | Hearing loss (hearing impairment) |
Growth and development | 1 | Short stature |
Lab test results | 1 | Elevated circulating alpha-fetoprotein concentration |
Age of onset: at birth.
Primrose syndrome is a rare disorder characterized by macrocephaly with developmental delay, intellectual disability, behavioral issues, a recognizable facial phenotype, altered glucose metabolism, hearing loss, ocular anomalies, cryptorchidism, and unique imaging findings including calcification of the ear cartilage . To date, 52 individuals have been identified with a pathogenic variant in ZBTB20 . The following description of the phenotypic features associated with this condition is based on these reports.
Table 2.
Primrose Syndrome: Frequency of Select Features
Feature | # (%) of Personsw/Feature
Characteristic
facial features | High anterior hairline | 25/32 (78%)
Ptosis | 23/31 (74%)
Large ears | 27/39 (69%)
Downslanted palpebral fissures | 21/37 (57%)
High palate | 12/26 (46%)
Source: GeneReviews — "Primrose Syndrome"
Table 3.
Genes of Interest in the Differential Diagnosis of Primrose Syndrome
Gene(s) / Genetic Mechanism | DiffDx Disorder | MOI | Clinical Features of DiffDx Disorder
Overlapping w/Primrose syndrome | Distinguishing from Primrose syndrome
1.5- to 1.8-Mb duplication at 7q11.23 | 7q11.23 duplication syndrome | AD | Behavioral facial phenotype, DD | Congenital malformations, cardiovascular disease, GI issues
3q13.31 deletion1 | 3q13.31 deletion syndrome2 (OMIM 615433) (See also .) | AD | Autism; macrocephaly; ear cartilage calcification; diabetes | Distinct facial gestalt; feeding difficulties, ataxia, neuropsychiatric manifestations
FMR1 | Fragile X syndrome (See FMR1 Disorders.) | XL | Autism, DD | Less prominent macrocephaly; distinctive facial features
GPC3
Source: GeneReviews — "Primrose Syndrome"
Genetic testing for ZBTB20 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for Primrose syndrome has been reported in the published literature.
System/Concern | Evaluation | Comment |
|---|---|---|
Development | Developmental assessment | To incl motor, adaptive, cognitive, speech-language eval; Eval for early intervention/ special education Speech |
development | Speech therapy eval | Delayed speech is a major concern should be addressed early. Motor |
development | Orthopedics/ physical medicine rehab/ PT OT eval | To incl assessment of:; Gross motor fine motor skills; Mobility, ADL, need for adaptive devices; Need for PT (to improve gross motor skills) /or OT (to improve fine motor skills) Psychiatric/ |
Behavioral | Neuropsychiatric eval | Persons age 12 mos: screen for behavior concerns incl sleep disturbances, ADHD, anxiety, /or traits suggestive of ASD. |
Neurologic | Neurologic eval | To incl brain MRI; Consider EEG if seizures are a concern. |
Skeletal | Skeletal survey | To detect genu varus valgus deformity plan early correction |
Hearing | Brain stem evoked response audiometry pure tone audiogram | Endocrine |
Eyes | Ophthalmology exam for cataract, ptosis, strabismus | Genetic |
counseling | By genetics professionals1 | To inform affected persons their families re nature, MOI, implications of Primrose syndrome to facilitate medical personal decision making Family support resources |
Treatment of Manifestations in Individuals with Primrose Syndrome Manifestation/Concern | Treatment | Considerations/Other DDD/ID |
ADHD | Therapy as recommended by developmental pediatrician | Most children are hyperactive medications should be reserved for severe manifestations. |
Autism | Standard treatment of ASD, incl applied behavior analysis (ABA) therapy. | ABA therapy is targeted to individual child's behavioral, social, adaptive strengths weaknesses; typically performed one on one w/board-certified behavior analyst. Other behavior disorders |
Seizures | Standardized treatment w/ASM by experienced neurologist | Many ASMs may be effective; none has been demonstrated effective specifically for this disorder.; Education of parents/caregivers1 |
Skeletal | Refer to an orthopedist for surgical correction of deformities as indicated. | Muscle wasting / Contractures / |
Ataxia | Orthopedics/ physical medicine rehab/ PT OT incl stretching to help avoid contractures falls | Consider need for positioning mobility devices, disability parking placard. |
Hearing loss | Consider hearing aids referral to otolaryngologist. | Community hearing services through early intervention or school district |
Diabetes | Consider insulin/oral hypoglycemics in consultation w/endocrinologist. | Thyroid |
dysfunction | Treatment per endocrinologist | ADHD = attention-deficit/hyperactivity disorder; ASD = autism spectrum disorder; ASM = anti-seizure medication; DD/ID = developmental delay / intellectual disability; IEP = individualized education program; OT = occupational therapy; PT = physical therapy 1. |
Source: GeneReviews — "Primrose Syndrome"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Primrose Syndrome"
View trials for Primrose syndrome
Evaluation
Frequency |
|---|
Growth | Anthropometry, clinical exam | Every 6 mos Speech development |
Behavioral | Behavioral assessment for anxiety, attention, aggressive or self-injurious behavior | At each visit Seizures |
Hearing | Brain stem evoked response audiometry | Annually or as indicated Endocrine |
Source: GeneReviews — "Primrose Syndrome"
Phenotype severity distribution: 3 always present features, 7 very common features, 28 common features.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
46 |
32% |
Patient case studies | 26 | 18% |
Disease patterns and progression | 15 | 10% |
Testing and diagnosis research | 7 | 5% |
Clinical study results | 3 | 2% |
New treatment approaches | 2 | 1% |
Vlami K (2026). [PMID: 41751879](https://pubmed.ncbi.nlm.nih.gov/41751879/). *Int J Mol Sci*. [Case Report / Case Series]
Thakral A (2026). [PMID: 42060581](https://pubmed.ncbi.nlm.nih.gov/42060581/). *Clin Dysmorphol*. [Case Report / Case Series]
Radio FC (2026). [PMID: 41904678](https://pubmed.ncbi.nlm.nih.gov/41904678/). *Genet Med*. [Basic Science / Preclinical]
Winters R (2026). [PMID: 31334998](https://pubmed.ncbi.nlm.nih.gov/31334998/). *Unknown Journal*. [Basic Science / Preclinical]
Pichon E (2026). [PMID: 41025404](https://pubmed.ncbi.nlm.nih.gov/41025404/). *Movement disorders clinical practice*. [Review / Meta-Analysis]
Chauhan M (2026). [PMID: 42074498](https://pubmed.ncbi.nlm.nih.gov/42074498/). *Genes (Basel)*. [Review / Meta-Analysis]
Khan A (2026). [PMID: 41486098](https://pubmed.ncbi.nlm.nih.gov/41486098/). *American journal of medical genetics. Part A*. [Basic Science / Preclinical]
Hindermann M (2026). [PMID: 41729076](https://pubmed.ncbi.nlm.nih.gov/41729076/). *JCI insight*. [Diagnostic / Biomarker]
Xu X (2026). [PMID: 42138082](https://pubmed.ncbi.nlm.nih.gov/42138082/). *J Clin Invest*. [Basic Science / Preclinical]
Anderson EN (2026). [PMID: 41468891](https://pubmed.ncbi.nlm.nih.gov/41468891/). *American journal of human genetics*. [Basic Science / Preclinical]